Coya Therapeutics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $8M+125.6% YoYTTM through 30 Jun 2026
Net Income -$21.7MTTM through 30 Jun 2026
Free Cash Flow -$15.7MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| EBITDA Margin | -288.5% |
| Operating Margin | -283.9% |
| Net Margin | -270.2% |
Returns
-49.3%ROE
-42.5%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio8.67x
Net Debt-$46.8Mnet cash position
Cash & Equivalents$43.2M
Quality Metrics
Altman Z-Score15.92
Piotroski F-Score2 / 9
FCF Margin-196.1%
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2025: $7.9M
Diluted EPS-$1.07TTMFY2025: $-1.27
Dividend
No dividend
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Collaboration and Licensing | $7.9M | +122.9% | View detailsAdvancing clinical trials and expanding pipeline modalities. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.